The dilemma of screening for prostate cancer

October 14, 2015, Wiley
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Primary care providers are put in a difficult position when screening their male patients for prostate cancer—some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients. Now a new perspective piece offers some guidance on when to screen patients and how to involve them in decisions about screening and treatment.

The authors believe that primary care providers should screen men 45 years of age and older who have a 10 year for prostate cancer with a (DRE) and a prostate-specific antigen (PSA) test. Providers should educate the patient that both are tools to evaluate the prostate and screen for cancer. If the patient wants more information, then the provider should engage in the discussion, but if the provider is uncomfortable, or does not have sufficient time, the patient should be referred to someone who can help. If the DRE is normal and the PSA is less than 1.5 ng/ml, the provider should consider a 5-year screening interval. If the DRE is abnormal or the PSA is 1.5 ng/ml or greater, the patient should be referred to a specialist. A biopsy should not be performed unless the risk of an is significant, and this should be discussed thoroughly with the patient.

"The primary care provider is on the front line with regards to early detection of prostate cancer. In fact, they are responsible for 90% of the labs drawn in screening," said Dr. Matt Rosenberg, lead author of the International Journal of Clinical Practice article. "Getting rid of the evaluation for prostate cancer altogether is a bad idea, but intelligently using the tools we have is certainly within the best interest of our patients."

Explore further: New prostate cancer screening review article advocates for active surveillance

Related Stories

New prostate cancer screening review article advocates for active surveillance

September 17, 2015
In the wake of changing guidelines related to prostate cancer screening, a newly published review article out of University Hospitals Case Medical Center's Seidman Cancer Center in Cleveland provides important guidance about ...

Age, life expectancy influence termination of PSA screening

April 26, 2012
(HealthDay) -- Most primary care providers consider both a man's age and life expectancy in deciding whether to discontinue prostate-specific antigen (PSA) screenings, but multiple factors are involved in this decision, according ...

New prostate cancer screening guideline recommends not using PSA test

October 27, 2014
A new Canadian guideline recommends that the prostate-specific antigen (PSA) test should not be used to screen for prostate cancer based on evidence that shows an increased risk of harm and uncertain benefits. The guideline ...

Digital rectal exam remains important part of prostate screening

March 18, 2013
(Medical Xpress)—The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to ...

More men at risk for prostate cancer as a result of less regular screening

September 22, 2015
The U.S. Preventive Services Task Force (USPSTF) recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.